

HCCI

HCCI Management Services Inc.

September 11, 1992

Edward A. Greenhalgh
265-7 Regina Street North
WATERLOO, Ontario
N2J 3B9

Dear Mr. Greenhalgh:

Upon reading the documentation you forwarded to me Aug. 31st, which illustrates your impressive educational background, I can understand your sentiments on receiving notice of a job at our Resco Plant for general labourer positions. I would however, like to clarify that it is the responsibility of Resources representatives to advise all our employees after the recent business changes of any job openings available in our organization. This gesture on our part is in no way to lessen the importance of our employees' qualifications, but forwarded to all the Cambridge employees concerned.

It is a fact that our North American business oriented towards the marketing of our product line and not in the scientific research. Therefore, we cannot sponsor the research project you have presented.

I have asked Mr. Jean-Pierre Kolo to contact you in future to assess with you if there are any other avenues you could explore.

I am confident that your experience and perseverance you to a successful career and I wish you the best of luck in future endeavours.

Yours truly,

Alban W. Schuele

Edward A. Greenhalgh
265-7 Regina St. N.
Waterloo, Ontario
N2J 3B9
(519) 884-3318

25 August 1992

President A. W. Schuele
Hoechst Canada Inc.
P.O.B. 6160, Station A
Montreal, Quebec
H3C 3K8

Dear President Schuele:

I am writing an update to my 31 July 1992 letter. Your response can be considered no worse than other pharmaceutical firms. Those whose main goals are not exactly as my proposal wrote back saying so and wishing me well. The few firms where my proposal was exactly what their industry is based upon have simply avoided the issue. Although you are no worse than the industry standard; however, according to Quality Assurance, and Road Map to Problem Solving, shouldn't you want to be better?

Please note the kind reply to my request for scientific papers from Dr. Ohno (21 July 1992 - The Ben Horowitz Chair of Distinguished Scientist...). On a strictly scientific basis I receive considerable worldwide courtesy still. On a strictly scientific basis I wish to update my proposal and its benefit. Please contact Dr. Kott as I have explained the theoretical details to him; and if my theory (of evolution) is correct the benefits are immense. If I am correct, I may be able (within a year) to produce a protein responsible for remission. The protein could then be mass produced by genetic engineering. Is Hoechst going to turn such a project down? Again we can "brainstorm" the possibilities.

On a sadder note, a poor individual (24 Aug. 1992) has settled a foolish dispute with Concordia by murdering people. A tragedy. I asked you to read a Time magazine article concerning academic problems; further many people in the USA have settled dispute similarly. I, too, have been involved in an academic dispute; however, like Ms. O'Toole (and any proper pharmaceutical firm) I have retained legal counsel. McMillan and Binch is proceeding with my plagiarism charge: such a responsible firm would not do so unless they were very convinced of the validity of the case. I have watched positions in England and the US disappear while driving a forklift for Hoechst. Nevertheless, I kept a good work record, a positive attitude and paid my bills (the Province has announced it is going after students who have defaulted their loans as far back as 1965). Do I not fit your Quality Values as the type of individual your QA program states you should support.

Why not meet with me and discuss the project? Taxol will soon be on the market, so why not have an equally valid alternative? I honestly do not see you risking very much capital on the project, while the returns are potentially incredible.

- i. A simple, i.e., anti-body test could be developed for a reliable “over-the-counter” AIDS test. There may be several levels of the disease and each could be identified. The potential is significant.
- ii. If each state can be recognized, then different drug regimen may be used to “break the chain” and interrupt the disease with a less drastic therapy. Similarly, cancer treatments could be examined on this experimental theme.

Part Two: The Basic Research

To explore the theoretical work demonstrating the possibility that viruses are the basis of life representing a “living crystal” concept controlled by the laws of thermodynamics. One experiment would make energy measurements based on the theoretical paper’s mathematical predictions (work presently in progress). Then, an experimental model would be designed: i.e., the original prototype cell (a protocyte, to coin a phrase), from a virus, a protein and a micelle/vesicle. Another area would examine viral induced lysis in cells — the actual genes activated plus the formed products from a variety of infected bacteria. These would then be compared to an evolved cell model. One such model is the luteal cell and regression lysis. By comparing the gene sequences, lysis as evolutionary conservation may be explored. Part of the evolutionary study is the central theorem of the conservation of genes (a vivid example is the use of coral in bone surgery). Coral is quickly accepted by the body. Similar genes from two dissimilar organisms: the genes were conserved to be utilized by higher organisms.

The lysis mechanism (see my papers v125(3) J. Endo 1990 and the mention of a possible cell death signal), related parts and functions, should prove, on a wide scale, to be of medical importance.

Lysis and cell death (for a variety of cells). There may be a common (conserved) gene sequence with related (i.e., enzyme) components that are activated.

The Important Occurrences: red blood cells and aging; muscle atrophy which may be healthy (i.e., the decrease in uterium size post partum) or dangerous (i.e., heart damage as in ischemia and heart disease).

Why cancer cells do not lyse. Either because the gene sequence is absent or blocked. Therefore, can the proper gene sequence be specified and the cancer cells then be given a specific signal and told to “die”, i.e., *with* a cell specific signal drug.



Basic Research Goals

- a. To discover how viruses were developed to seek and attach to the cell, etc.: all of which have significant consequences to viral control and drug delivery.
- b. How self and identity of self (of the cell and the environment) were developed.
- c. How control of lysis was developed with consequences to reproduction, arthritis and feedback to the brain.
- d. How the colony (higher organism) was developed: healthy coexistence and its implications.
- e. How the nucleus and genome evolved: how energy was stored in the nucleus and passed along.
- f. Development of membranes and how the proteins (enzymes) came to be placed in same. This has implications for disease control and drug delivery.